Riskpilot← Back to searchSign inGet full accessAkuveda AB
ABActiveOrg 5591333025Vidargatan 1Traditional, complementary and alternative medicine activities · NACE 8696Est. 20170 employees
Revenue 2025
SEK 444K
-8% vs 2024
EBITDA margin
11.8%
-28% vs 2024
Equity ratio
97.0%
Financial strength
Net profit 2025
SEK -47K
-15% vs 2024
| Revenue | SEK 444K | -8% |
| EBITDA | SEK 52K | -28% |
| Net profit | SEK -47K | -15% |
| Total assets | SEK 417K | -40% |
| Equity | SEK 405K | -38% |
| Employees | 0 | — |
Legal name
Akuveda AB
Org number
5591333025
Legal form
Aktiebolag
NACE code
8696 · Traditional, complementary and alternative medicine activities
Founded
10 november 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Panabokke, Shani Lalanika
Company purpose
Föremålet för bolagets verksamhet är akupunktur, massage, hudvård försäljning av hälsoprodukter och därmed förenlig verksamhet.
Address
Vidargatan 1
Email
info@akuveda.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 6 994 | 923 | 662 | 484 | 444 |
| Staff expenses | — | −962 | −482 | −50 | −23 |
| EBITDA | 2 255 | −580 | −268 | 73 | 52 |
| Depreciation & amort. | −22 | −114 | −114 | −113 | −100 |
| EBIT | 2 233 | −694 | −382 | −40 | −48 |
| Net financials | — | 0 | 8 | −0 | 1 |
| Profit before tax | 1 565 | −26 | −361 | −41 | −47 |
| Tax | −325 | — | — | — | — |
| Net profit | 1 240 | −26 | −361 | −41 | −47 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 515 | 1 594 | 867 | 701 | 417 |
| Equity | 1 380 | 1 154 | 792 | 652 | 405 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 454 | 428 | 75 | 49 | 12 |
| Total debt | 454 | 428 | 75 | 49 | 12 |
EBITDA margin
11.8%
This company
15.8%
Market median
-25% vs market
20212025
Equity ratio
97.0%
This company
38.2%
Market median
+154% vs market
20212025
Return on equity
-11.5%
This company
18.4%
Market median
-163% vs market
20212025
Net profit margin
-10.5%
This company
8.1%
Market median
-230% vs market
20212025
Asset turnover
1.06×
This company
1.12×
Market median
+5% vs market
20212025
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SL Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
| Former (2) | ||
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Akuveda AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Shani Lalanika Panabokke | Chief Executive Officer | 0 companies |
| Anders Martin Forss | Board of Directors | 0 companies |
| Inga-Lill Anna Märtha Stålåker | Board of Directors | 0 companies |
| K Lihini Wijesinghe Panabokke | Deputy Board Member | 0 companies |